Exploring the next generation of antibody–drug conjugates

Nature Reviews Clinical Oncology, Published online: 08 January 2024; doi:10.1038/s41571-023-00850-2Antibody–drug conjugates (ADCs) are effective cancer drugs that have been approved for more than 20 specific indications. Nonetheless, acquired resistance and adverse events both limit the effectiveness of these agents. In this Review, the authors describe the development of novel ADC designs, including bispecific ADCs, probody–drug conjugates, immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs. all of which have the potential to address these challenges and provide more effective ADCs.

Source: Nature Reviews Clinical Oncology - January 8, 2024 Category: Cancer & Oncology Authors: Kyoji Tsuchikama Yasuaki Anami Summer Y. Y. Ha Chisato M. Yamazaki Source Type: research